Aerosolized beclomethasone in chronic bronchitis: Improved pulmonary function and diminished airway inflammation

A. B. Thompson, M. B. Mueller, A. J. Heires, T. L. Bohling, D. Daughton, S. W. Yancey, R. S. Sykes, S. I. Rennard

Research output: Contribution to journalArticle

92 Scopus citations

Abstract

Chronic bronchitis is associated with airways obstruction and inflammation. In order to determine whether aerosolized beclomethasone can modulate airway inflammation and diminish airway obstruction, subjects with chronic bronchitis performed spirometry and underwent bronchoalveolar lavage (BAL) before and after receiving 6 wk of therapy (five puffs four times a day) with either aerosolized beclomethasone (n = 20) or placebo (n = 10) in a double-blinded, randomized fashion. All subjects received aerosolized albuterol before each use of the study medications. Before BAL, the airways were visually assessed for the appearance of inflammation and assigned a score, the bronchitis index. BAL was performed by instilling five 20-ml aliquots of saline into each of three sites and pooling and separately analyzing the returns from the first aliquots to yield a 'bronchial sample.' The bronchial lavages were repeated in an additional three sites to increase the volume of fluid available for analysis. The fluid was prepared for cytologic examination by cytocentrifugation. Albumin (as a measure of epithelium permeability) and lactoferrin and lysozyme (as measures of serous cell activity) were measured in unconcentrated BAL fluid by enzyme-linked immunosorbent assay, and concentrations in epithelial lining fluid were estimated using urea as an internal marker for dilution. After treatment, the beclomethasone group, but not the placebo group, showed improvement in FVC (p = 0.02), FEV1 (p = 0.002), and 25 to 75% forced expiratory flow (p = 0.006). Associated with the improvement in spirometry, the bronchitis index fell (13.5 ± 1.0 versus 10.75 ± 1.1, p = 0.02) in the beclomethasone-treated group, but not the placebo-treated group. Compared with the placebo-treated group, the beclomethasone-treated subjects demonstrated an improvement in bronchial sample cell count (p = 0.048) and epithelial lining fluid albumin (p = 0.018), lactoferrin (p = 0.014), and lysozyme (p = 0.046). Thus, treatment of chronic bronchitis with aerosolized beclomethasone led to a statistically significant improvement in spirometry associated with modulation of parameters of airway inflammation.

Original languageEnglish (US)
Pages (from-to)389-395
Number of pages7
JournalAmerican Review of Respiratory Disease
Volume146
Issue number2
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Aerosolized beclomethasone in chronic bronchitis: Improved pulmonary function and diminished airway inflammation'. Together they form a unique fingerprint.

  • Cite this

    Thompson, A. B., Mueller, M. B., Heires, A. J., Bohling, T. L., Daughton, D., Yancey, S. W., Sykes, R. S., & Rennard, S. I. (1992). Aerosolized beclomethasone in chronic bronchitis: Improved pulmonary function and diminished airway inflammation. American Review of Respiratory Disease, 146(2), 389-395. https://doi.org/10.1164/ajrccm/146.2.389